| 1 |
NCT02876107 |
Recruiting |
A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC) |
- Malignant Neoplasm of Breast
|
- Procedure: Breast Core Biopsy
- Drug: Paclitaxel
- Drug: Carboplatin
- (and 6 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Amgen
- M.D. Anderson Cancer Center
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Pathologic Response (pCR) Rate
- Disease-Free Survival (DFS) Rate
|
72 |
Female |
18 Years and older (Adult, Senior) |
NCT02876107 |
2016-0177
NCI-2017-00619 |
|
October 2016 |
October 2023 |
October 2024 |
August 23, 2016 |
February 19, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 2 |
NCT02971748 |
Recruiting |
A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy |
- Inflammatory Breast Cancer
- Malignant Neoplasm of Breast
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival (DFS)
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT02971748 |
2016-0096 |
|
January 26, 2017 |
January 2020 |
January 2021 |
November 23, 2016 |
February 28, 2018 |
|
- The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 3 |
NCT03202316 |
Recruiting |
Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer |
- Malignant Neoplasm of Breast
|
- Drug: Cobimetinib
- Drug: Atezolizumab
- Drug: Eribulin
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Genentech, Inc.
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Cobimetinib Plus Atezolizumab and Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- Overall Response Rate (ORR) of Cobimetinib Plus Atezolizumab and Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- Clinical Benefit Rate (CBR) of Cobimetinib Plus Atezolizumab and Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- (and 3 more...)
|
33 |
Female |
18 Years and older (Adult, Senior) |
NCT03202316 |
2016-0890
NCI-2017-01601 |
|
August 11, 2017 |
August 2020 |
August 2021 |
June 28, 2017 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 4 |
NCT02411656 |
Recruiting |
MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC) |
|
- Drug: MK-3475
- Behavioral: Follow Up/Phone Call
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT02411656 |
2014-0533
NCI-2015-00671 |
|
June 2015 |
June 2020 |
June 2021 |
April 8, 2015 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 5 |
NCT01325428 |
Completed
Has Results |
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer |
|
- Drug: Afatinib once daily (OD)
- Drug: Vinorelbine Weekly
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part A: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
- Part B: Clinical Benefit (CB) Assessed by Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at Least 6 Months Using the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
- Part A: Confirmed Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST 1.1).
- (and 8 more...)
|
26 |
Female |
18 Years and older (Adult, Senior) |
NCT01325428 |
1200.89
2010-024454-10 |
|
August 2011 |
November 2014 |
November 2014 |
March 29, 2011 |
July 19, 2016 |
February 11, 2016 |
- 1200.89.10001 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States - 1200.89.10005 Boehringer Ingelheim Investigational Site
Durham, North Carolina, United States - 1200.89.61002 Boehringer Ingelheim Investigational Site
East Bentleigh, Victoria, Australia - (and 13 more...)
|
| 6 |
NCT02324088 |
Completed |
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer |
- Inflammatory Breast Cancer
|
- Drug: Docetaxel
- Drug: Cyclophosphamide
- Drug: Epirubicin
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- disease-free survival rate
|
174 |
Female |
18 Years to 60 Years (Adult) |
NCT02324088 |
PEGASE 7/0002 |
PEGASE07 |
October 2000 |
December 2012 |
January 2015 |
December 24, 2014 |
May 8, 2017 |
|
|
| 7 |
NCT01262027 |
Active, not recruiting
Has Results |
TKI258 for Metastatic Inflammatory Breast Cancer Patients |
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Novartis
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of Participants
- Safety Analysis of Dovitinib: Most Frequently Reported Treatment-related Adverse Event (AEs)
|
22 |
Female |
18 Years and older (Adult, Senior) |
NCT01262027 |
2010-0296
NCI-2011-00299 |
|
January 27, 2012 |
November 2015 |
December 2017 |
December 17, 2010 |
June 15, 2017 |
February 2, 2017 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 8 |
NCT00118053 |
Terminated
Has Results |
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer |
|
- Biological: herceptin
- Drug: carboplatin
- Drug: docetaxel
- (and 2 more...)
|
Interventional |
Phase 2 |
- University of Medicine and Dentistry of New Jersey
- National Cancer Institute (NCI)
- Aventis Pharmaceuticals
- Rutgers, The State University of New Jersey
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Antitumor Activity as Measured by Response Rate
- Pathological Complete Response
- Disease-free Survival
- Pathologic and Molecular Markers for Predicting Efficacy
|
5 |
Female |
18 Years and older (Adult, Senior) |
NCT00118053 |
040412;CDR0000433511
P30CA072720
CINJ-040412
0220045191
CINJ-NJ1104 |
|
April 2005 |
December 2008 |
December 2008 |
July 11, 2005 |
November 20, 2013 |
November 20, 2013 |
- Central Jersey Oncology Center, PA - East Brunswick
East Brunswick, New Jersey, United States - CentraState Medical Center
Freehold, New Jersey, United States - Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States - (and 6 more...)
|
| 9 |
NCT00558103 |
Completed
Has Results |
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer |
|
- Drug: lapatinib
- Drug: Pazopanib
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants With Overall Response (OR), Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR), Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions
- Median Duration of Response,Defined as the First Documented Evidence of CR or PR Until the First Documentation of Disease Progression
- Progression-free Survival, Defined as the Interval Between the Date of Randomization and the Earliest Date of Disease Progression (PD) or Death Due to Any Cause (Defined by an Investigator Review of Lesions Based on RECIST and Cutaneous Disease)
- Overall Survival
|
163 |
Female |
18 Years and older (Adult, Senior) |
NCT00558103 |
VEG108838 |
|
December 2007 |
May 2011 |
December 2011 |
November 14, 2007 |
February 4, 2013 |
July 18, 2012 |
- GSK Investigational Site
Long Beach, California, United States - GSK Investigational Site
Sacramento, California, United States - GSK Investigational Site
Denver, Colorado, United States - (and 123 more...)
|
| 10 |
NCT02623972 |
Recruiting |
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer |
- Inflammatory Breast Cancer
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
|
- Drug: Eribulin
- Drug: Adriamycin
- Drug: Cyclophosphamide
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Eisai Inc.
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic Complete Response
- Disease Free Survival
- Time to Treatment Failure
- (and 4 more...)
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT02623972 |
15-292 |
|
December 2015 |
February 2019 |
February 2023 |
December 8, 2015 |
July 2, 2017 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 11 |
NCT01938833 |
Terminated
Has Results |
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer |
- HER2-negative Breast Cancer
- Inflammatory Breast Cancer
- Male Breast Cancer
- (and 2 more...)
|
- Drug: Romidepsin
- Drug: Abraxane
|
Interventional |
Phase 1
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Celgene Corporation
- Thomas Jefferson University
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-Tolerated Dose of Romidepsin (Phase I)
- Progression-Free Survival (PFS)
- Incidence of Adverse Events, Graded According to NCI CTCAE Version 4.0
- (and 2 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT01938833 |
13C.387
2013-035 |
|
April 2014 |
August 18, 2016 |
December 8, 2016 |
September 10, 2013 |
December 28, 2017 |
September 29, 2017 |
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
| 12 |
NCT02876302 |
Recruiting |
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer |
- Inflammatory Breast Cancer (IBC)
|
- Drug: Ruxolitinib
- Drug: Paclitaxel
- Drug: Doxorubicin
- Drug: Cyclophosphamide
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Incyte Corporation
- Dana-Farber Cancer Institute
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Assess JAK Inhibition With Ruxolitinib On pStat3+ Expression
- Determine Pathologic Complete Response rate (pCR) after preoperative therapy
- Correlate effects on pSTAT3+ and STAT3 gene expression with pCR
- (and 9 more...)
|
64 |
All |
18 Years and older (Adult, Senior) |
NCT02876302 |
16-151 |
|
April 26, 2017 |
February 2020 |
February 2024 |
August 23, 2016 |
April 25, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - Johns Hopkins at Green Spring Station
Lutherville, Maryland, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - (and 2 more...)
|
| 13 |
NCT02389764 |
Active, not recruiting |
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC) |
|
- Drug: BIBF 1120
- Behavioral: Phone Call
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Boehringer Ingelheim
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinical Benefit Rate (CBR) of BIBF-1120 in Metastatic Inflammatory Breast Cancer (IBC)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02389764 |
2014-0464
NCI-2015-00506 |
|
June 2015 |
June 2022 |
June 2023 |
March 17, 2015 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 14 |
NCT00646555 |
Completed |
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT00646555 |
999904051
04-C-N051 |
|
November 20, 2003 |
|
April 10, 2012 |
March 28, 2008 |
July 2, 2017 |
|
- GW University Medical Center GW Hospital Center
Washington, D.C., District of Columbia, United States
|
| 15 |
NCT00793390 |
Completed |
Case-Control Study of Inflammatory Breast Cancer in North Africa |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
|
773 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT00793390 |
999909033
09-C-N033 |
|
November 17, 2008 |
|
|
November 19, 2008 |
April 17, 2018 |
|
- National Cancer Institute-Cairo
Cairo, Egypt - Gharbia Cancer Society
Gharbia, Egypt - Tanta Cancer Center
Tanta, Egypt - (and 3 more...)
|
| 16 |
NCT00005822 |
Completed |
SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer |
|
- Drug: doxorubicin hydrochloride
- Drug: semaxanib
- Procedure: conventional surgery
- (and 2 more...)
|
Interventional |
Phase 1 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
- Case Comprehensive Cancer Center
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the maximum tolerated dose of SU5416 and doxorubicin in patients with stage IIIB or IV inflammatory breast cancer.
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT00005822 |
CWRU5199
U01CA062502
P30CA043703
CWRU-5199
NCI-T99-0099 |
|
April 2000 |
December 2002 |
October 2003 |
January 27, 2003 |
June 11, 2010 |
|
- Ireland Cancer Center at University Hospitals Case Medical Center
Cleveland, Ohio, United States
|
| 17 |
NCT01880385 |
Unknown † |
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer |
- Inflammatory Breast Cancer
|
- Biological: Bevacizumab
- Drug: Cyclophosphamide
- Drug: epirubicin hydrochloride
- (and 3 more...)
|
Interventional |
Phase 1 |
- Association Tunisienne de lutte Contre le Cancer
- Hoffmann-La Roche
- Sanofi
- Association Tunisienne de lutte Contre le Cancer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- pathologic Complete Response (pCR)
- Toxicity as assessed by CTCAE v3.0
- Progression-free survival
- Overall survival
|
30 |
Female |
20 Years to 75 Years (Adult, Senior) |
NCT01880385 |
ML25168 |
Beva |
March 2011 |
September 2013 |
April 2017 |
June 19, 2013 |
June 19, 2013 |
|
- Institut Salah Azaiz
Bab Saadoun, Tunis, Tunisia
|
| 18 |
NCT00016549 |
Completed |
Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer |
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
- To determine in IBC or LABC whether a change in any of the 4 angiogenesis parameters; 3 primary molecular parameters or the dynamic MRI parameter can be detected from baseline to 3 wks after treatment with bevacizumab.
- To attempt to correlate each of the four primary parameters with clinical findings and time to progression/recurrence.
|
21 |
All |
18 Years and older (Adult, Senior) |
NCT00016549 |
010173
01-C-0173 |
|
May 13, 2001 |
January 29, 2007 |
January 29, 2007 |
May 17, 2001 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 19 |
NCT03101748 |
Recruiting |
A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC |
- Malignant Neoplasm of Breast
|
- Drug: Neratinib
- Drug: Paclitaxel
- Drug: Pertuzumab
- (and 3 more...)
|
Interventional |
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- Puma Biotechnology, Inc.
- M.D. Anderson Cancer Center
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Neratinib in Combination with Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive (HER2+) Primary Metastatic or Locally Advanced Breast Cancer
- Pathologic Complete Response (pCR) Rate of Neratinib in Combination with Paclitaxel, Pertuzumab, and Trastuzumab Followed by Doxorubicin and Cyclophosphamide (AC) in HER2+ Locally Advanced Inflammatory Breast Cancer (IBC) Patients
- Pathologic Complete Response (pCR) Rate of Neratinib in Combination with Paclitaxel Followed by Doxorubicin and Cyclophosphamide in HER2-Negative/ER-Positive (HER2-/ER+) Locally Advanced Inflammatory Breast Cancer (IBC) Patients
- Progression Free Survival (PFS) Rate of HER2+ Primary de novo Metastatic and Locally Advanced Inflammatory Breast Cancer (IBC) Patients, and HER2-/ER+ IBC Patients Treated with Neratinib Plus Anthracycline and Taxane Based Chemotherapy
|
99 |
Female |
18 Years and older (Adult, Senior) |
NCT03101748 |
2016-0537
NCI-2017-00813 |
|
January 29, 2018 |
January 2026 |
January 2027 |
April 5, 2017 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 20 |
NCT00193206 |
Completed
Has Results |
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer |
|
- Drug: Gemcitabine
- Drug: Epirubicin
- Drug: Albumin-bound Paclitaxel
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- Eli Lilly and Company
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic Complete Response
- Clinical Response Rates
- Time to Disease Progression
- Rates of Breast Preservation
|
123 |
Female |
18 Years and older (Adult, Senior) |
NCT00193206 |
SCRI BRE 73 |
|
September 2005 |
October 2008 |
May 2009 |
September 19, 2005 |
November 30, 2012 |
November 30, 2012 |
- Florida Cancer Specialists
Fort Myers, Florida, United States - Integrated Community Oncology Network
Jacksonville, Florida, United States - Watson Clinic Center for Cancer Care and Research
Lakeland, Florida, United States - (and 10 more...)
|
| 21 |
NCT00344071 |
Completed |
Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia |
- Inflammatory Breast Cancer
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
250 |
All |
Child, Adult, Senior |
NCT00344071 |
999904284
04-C-N284 |
|
September 8, 2004 |
April 27, 2007 |
|
June 26, 2006 |
July 2, 2017 |
|
- Cairo University Hospital
Cairo, Egypt - National Cancer Institute-Cairo
Cairo, Egypt - Association Tunisienne de lutte contre le Cancer (ATCC, le conseil
Tunis, Tunisia - Charles Nicolle Hospital, Tunisia
Tunis, Tunisia
|
| 22 |
NCT00340158 |
Completed |
Establishing an Inflammatory Breast Cancer Registry |
- Inflammatory Breast Cancer
|
|
Observational |
|
- National Cancer Institute (NCI)
- United States Department of Defense
- National Institutes of Health Clinical Center (CC)
|
NIH / U.S. Fed |
- Time Perspective: Retrospective
|
|
164 |
Female |
18 Years and older (Adult, Senior) |
NCT00340158 |
999903214
03-C-N214 |
|
June 2003 |
|
|
June 21, 2006 |
April 23, 2010 |
|
- National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 23 |
NCT00477100 |
Recruiting |
Inflammatory Breast Cancer (IBC) Registry |
|
- Other: Interview
- Procedure: Blood and Tissue Collection
|
Observational |
|
- M.D. Anderson Cancer Center
- Susan G. Komen Breast Cancer Foundation
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Number of patients with untreated newly diagnosed IBC participating in Registry
|
1200 |
All |
18 Years and older (Adult, Senior) |
NCT00477100 |
2006-1072 |
|
April 2007 |
April 2020 |
April 2021 |
May 22, 2007 |
March 7, 2018 |
|
- City of Hope
Duarte, California, United States - University of New Mexico
Albuquerque, New Mexico, United States - University of Texas MD Anderson Cancer Center
Houston, Texas, United States - (and 16 more...)
|
| 24 |
NCT01231386 |
Recruiting |
MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer |
|
|
Observational |
|
- City of Hope Medical Center
|
Other |
- Observational Model: Cohort
- Time Perspective: Other
|
- Performance of miRNA profiling from tumor samples from primary breast tumors
- Assessment of miRNA profiles from blood/serum samples from patients at baseline, and if feasible, at different time points
- Analysis of miRNA findings and correlate miRNA patterns of expression in tumor, lymph nodes -if available- and in serum
- (and 4 more...)
|
165 |
Female |
18 Years and older (Adult, Senior) |
NCT01231386 |
09147 |
|
November 2009 |
May 2018 |
May 2018 |
November 1, 2010 |
August 22, 2017 |
|
- City of Hope
Duarte, California, United States
|
| 25 |
NCT00105950 |
Completed |
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response rate (complete response plus partial response)
- Clinical benefit (progression free survival, time to progression, response duration)
- Assessment of clinical benefit, defined as CR or PR for at least 4 weeks, or SD for at least 6 months
- (and 8 more...)
|
126 |
All |
18 Years and older (Adult, Senior) |
NCT00105950 |
EGF103009 |
|
March 2005 |
September 2007 |
May 2010 |
March 21, 2005 |
September 28, 2015 |
|
- GSK Investigational Site
Miami, Florida, United States - GSK Investigational Site
Chicago, Illinois, United States - GSK Investigational Site
Zion, Illinois, United States - (and 24 more...)
|
| 26 |
NCT00111787 |
Completed |
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer |
|
- Drug: Lapatinib
- Drug: Paclitaxel
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of participants with pathologic complete response rate (pCR)
- Percentage of participants with pCR that underwent surgical resection
- Percentage of participants with objective response rate (ORR) at the end of study (Response evaluation criteria in solid tumor [RECIST])
- (and 11 more...)
|
49 |
All |
18 Years and older (Adult, Senior) |
NCT00111787 |
EGF102580 |
|
April 11, 2005 |
November 1, 2006 |
November 1, 2006 |
May 26, 2005 |
May 31, 2017 |
|
- GSK Investigational Site
Miami, Florida, United States - GSK Investigational Site
Chicago, Illinois, United States - GSK Investigational Site
Zion, Illinois, United States - (and 22 more...)
|
| 27 |
NCT00756470 |
Terminated
Has Results |
Phase II Neoadjuvant in Inflammatory Breast Cancer |
|
- Drug: Lapatinib
- Drug: Paclitaxel
- Drug: 5-Fluorouracil (5-FU)
- (and 2 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- GlaxoSmithKline
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
- Number of Participants With pCR After Completion of All Protocol Specified Therapy & Surgery (Surgical Population)
|
15 |
Female |
18 Years and older (Adult, Senior) |
NCT00756470 |
2007-0818 |
|
October 2008 |
October 2013 |
October 2013 |
September 22, 2008 |
November 17, 2014 |
November 5, 2014 |
- UT MD Anderson Cancer Center
Houston, Texas, United States
|
| 28 |
NCT00820547 |
Active, not recruiting |
Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients |
|
- Biological: bevacizumab
- Drug: cyclophosphamide
- Drug: docetaxel
- (and 2 more...)
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete histologic response rate
- Progression-free survival
- Overall survival
- (and 4 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT00820547 |
PACS09 UC-0140/0802
UNICANCER-PACS-09-0802
EudraCT-2008-001807-53
EU-20889 |
Beverly1 |
January 2009 |
April 2015 |
March 2018 |
January 12, 2009 |
August 7, 2017 |
|
- Centre Paul Papin
Angers, France - Institut Sainte Catherine
Avignon, France - Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
Besancon, France - (and 25 more...)
|
| 29 |
NCT00066443 |
Completed |
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer |
|
- Biological: pegfilgrastim
- Drug: docetaxel
- Drug: epirubicin hydrochloride
|
Interventional |
Phase 1
Phase 2 |
- NCIC Clinical Trials Group
- Canadian Cancer Trials Group
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxic effects
- Response (phase II)
|
93 |
Female |
16 Years and older (Child, Adult, Senior) |
NCT00066443 |
MA22
CAN-NCIC-MA22
CDR0000316237 |
|
February 2003 |
January 2014 |
January 2014 |
August 7, 2003 |
November 3, 2015 |
|
- CancerCare Manitoba
Winnipeg, Manitoba, Canada - Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada - Odette Cancer Centre
Toronto, Ontario, Canada - (and 2 more...)
|
| 30 |
NCT00193050 |
Completed
Has Results |
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer |
|
- Drug: Gemcitabine
- Drug: Epirubicin
- Drug: Docetaxel
|
Interventional |
Phase 2 |
- SCRI Development Innovations, LLC
- Pharmacia and Upjohn
- Eli Lilly and Company
- Aventis Pharmaceuticals
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic Complete Response (pCR)
- Time to Treatment Failure (TTF)
- Overall Survival (OS)
|
110 |
Female |
18 Years and older (Adult, Senior) |
NCT00193050 |
SCRI BRE 51 |
|
November 2001 |
March 2008 |
March 2009 |
September 19, 2005 |
September 21, 2012 |
September 21, 2012 |
|
| 31 |
NCT00251329 |
Unknown † |
Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery |
|
- Drug: neoadjuvant chemotherapy
|
Interventional |
Phase 2 |
- Cancer Research Network
- Sanofi
- Cancer Research Network
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary objective of this study is to establish the pathological complete response rate (pCR) in the breast. The pCR is defined as the absence of invasive carcinoma.
- Establish pCR in breast and axillary lymph nodes
- Establish pCR in axillary lymph nodes
- (and 5 more...)
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT00251329 |
CRN-004 |
|
May 2003 |
|
|
November 10, 2005 |
April 4, 2007 |
|
- Baptist Cancer Institute
Jacksonville, Florida, United States - Lakeland Regional Cancer Center
Lakeland, Florida, United States - Mount Sinai Comprehensice Cancer Center
Miami, Florida, United States - (and 3 more...)
|
| 32 |
NCT01036087 |
Active, not recruiting |
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer |
|
- Drug: Panitumumab
- Drug: Nab-paclitaxel
- Drug: Carboplatin
- (and 3 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene Corporation
- Amgen
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic Complete Response (CR) Rate
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT01036087 |
2008-0372
NCI-2012-00935 |
|
November 2010 |
November 2018 |
November 2018 |
December 21, 2009 |
April 28, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 33 |
NCT00003680 |
Unknown † |
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer |
|
- Drug: CMF regimen
- Drug: cyclophosphamide
- Drug: fluorouracil
- (and 5 more...)
|
Interventional |
Phase 3 |
- Scottish Cancer Therapy Network
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
300 |
Female |
18 Years to 60 Years (Adult) |
NCT00003680 |
CDR0000066782
SCTN-BR9810
EU-98054 |
|
November 1998 |
|
|
May 3, 2004 |
November 6, 2013 |
|
- C.R.C. Beatson Laboratories
Glasgow, Scotland, United Kingdom
|
| 34 |
NCT03184558 |
Recruiting |
BGB324 in Combination With Pembrolizumab in Patients With TNBC |
- Triple Negative Breast Cancer
- Inflammatory Breast Cancer Stage IV
|
- Drug: BGB324; pembrolizumab
|
Interventional |
Phase 2 |
- BerGenBio ASA
- Merck Sharp & Dohme Corp.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Disease Control Rate
- Duration of Response
- (and 3 more...)
|
56 |
All |
18 Years and older (Adult, Senior) |
NCT03184558 |
BGBC007
MK-3475 PN530
2016-003608-30 |
|
July 26, 2017 |
December 2018 |
December 2019 |
June 12, 2017 |
January 4, 2018 |
|
- City of Hope Cancer Center
Duarte, California, United States - Sharp memorial Hospital, 7901 Frost Street,
San Diego, California, United States - Saint Luke's Cancer Institute
Kansas City, Missouri, United States - (and 14 more...)
|
| 35 |
NCT02041429 |
Active, not recruiting |
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca |
- Recurrent Breast Cancer
- Metastatic Breast Cancer
|
- Drug: Ruxolitinib
- Drug: Paclitaxel
|
Interventional |
Phase 1
Phase 2 |
- Dana-Farber Cancer Institute
- Incyte Corporation
- Dana-Farber Cancer Institute
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of ruxolitinib
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT02041429 |
13-494 |
|
February 2014 |
October 2017 |
January 2021 |
January 22, 2014 |
July 2, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 36 |
NCT00017095 |
Completed |
Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer |
|
- Biological: filgrastim
- Drug: cyclophosphamide
- Drug: docetaxel
- (and 9 more...)
|
Interventional |
Phase 3 |
- European Organisation for Research and Treatment of Cancer - EORTC
- Swedish Breast Cancer Group
- Swiss Group for Clinical Cancer Research
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival
- Distant metastasis-free survival
- Overall survival
- (and 5 more...)
|
1856 |
Female |
up to 70 Years (Child, Adult, Senior) |
NCT00017095 |
EORTC-10994-p53
EORTC-10994
ACCOG-EORTC-10994
SAKK-EORTC-10994
SBGC-EORTC-10994
BIG-1-00 |
|
March 2001 |
November 2006 |
|
January 27, 2003 |
October 24, 2013 |
|
- Institut Jules Bordet
Brussels, Belgium - CHU Liege - Domaine Universitaire du Sart Tilman
Liege, Belgium - Algemeen Ziekenhuis Sint-Augustinus
Wilrijk, Belgium - (and 36 more...)
|
| 37 |
NCT01796197 |
Active, not recruiting |
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa |
|
- Drug: Trastuzumab
- Drug: Pertuzumab
- Drug: Paclitaxel
- (and 4 more...)
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathologic complete response rate
- Assess residual cancer burden
- Assess toxicity of protocol therapy
- (and 4 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01796197 |
12-497 |
|
March 2013 |
June 2018 |
March 2020 |
February 21, 2013 |
February 12, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - University of Michigan
Ann Arbor, Michigan, United States
|
| 38 |
NCT00513695 |
Active, not recruiting
Has Results |
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer |
- Inflammatory Breast Cancer
- Male Breast Cancer
- Stage II Breast Cancer
- (and 3 more...)
|
- Drug: sunitinib malate
- Drug: paclitaxel
- Drug: doxorubicin hydrochloride
- (and 5 more...)
|
Interventional |
Phase 2 |
- University of Washington
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Microscopic Pathologic CR (pCR) Rate
- Clinical Complete Response and Correlation With Plasma VEGF, Soluble VCAM (sVCAM), and Circulating Endothelial Cells (CECs) Levels
- Relapse Rate
- (and 3 more...)
|
68 |
All |
Child, Adult, Senior |
NCT00513695 |
6488
NCI-2010-00607 |
|
June 2007 |
August 2012 |
|
August 9, 2007 |
June 14, 2017 |
May 10, 2017 |
- Anchorage Oncology Centre
Anchorage, Alaska, United States - Katmai Oncology Group
Anchorage, Alaska, United States - Arizona Cancer Center
Tucson, Arizona, United States - (and 4 more...)
|
| 39 |
NCT00001507 |
Completed |
Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer |
- Breast Neoplasm
- Neoplasm Metastasis
|
- Drug: Monoclonal Antibody 3A1
- Drug: Monoclonal Antibody 95-5-49
- Drug: Monoclonal Antibody 95-6-22
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
107 |
All |
18 Years and older (Adult, Senior) |
NCT00001507 |
960104
96-C-0104 |
|
July 12, 1996 |
June 30, 1998 |
June 20, 2014 |
November 4, 1999 |
October 6, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 40 |
NCT00957125 |
Active, not recruiting |
A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early |
|
- Drug: Epirubicin
- Drug: Docetaxel
- Drug: Bevacizumab
|
Interventional |
Phase 2 |
- Thomas Hatschek
- Karolinska University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluation of the sensitivity and of defined diagnostic and biological procedures to detect response/non-response to neoadjuvant treatment at an early point among patients with breast cancer.
- Identification of tumour characteristics and treatment-related changes of tumour characteristics predictive of long-term prognosis.
- Comparison between the standard evaluation procedures mammography, conventional ultrasound and clinical examination and functional imaging techniques and biological procedures with emphasis on detection of response at an early point of treatment.
- (and 3 more...)
|
151 |
Female |
18 Years and older (Adult, Senior) |
NCT00957125 |
PROMIX
2007-005858-23 |
PROMIX |
September 2008 |
November 2011 |
November 2016 |
August 12, 2009 |
September 8, 2016 |
|
- Sahlgrenska University Hospital
Göteborg, Sweden - Lund University Hospital
Lund, Sweden - Malmö General University Hospital
Malmö, Sweden - (and 3 more...)
|
| 41 |
NCT00003679 |
Unknown † |
Combination Chemotherapy in Treating Women With Breast Cancer |
|
- Drug: cyclophosphamide
- Drug: docetaxel
- Drug: doxorubicin hydrochloride
- (and 3 more...)
|
Interventional |
Phase 3 |
- Scottish Cancer Therapy Network
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
350 |
Female |
18 Years to 60 Years (Adult) |
NCT00003679 |
CDR0000066780
SCTN-BR9809
EU-98053 |
|
November 1998 |
|
|
December 5, 2003 |
November 6, 2013 |
|
- C.R.C. Beatson Laboratories
Glasgow, Scotland, United Kingdom
|
| 42 |
NCT02892734 |
Recruiting |
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer |
- HER2/Neu Negative
- Recurrent Inflammatory Breast Carcinoma
- Stage IV Breast Cancer
- Stage IV Inflammatory Breast Carcinoma
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- Northwestern University
- Bristol-Myers Squibb
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Response Rate (ORR)
- Clinical Benefit Rate (CBR)
- (and 2 more...)
|
29 |
Female |
18 Years and older (Adult, Senior) |
NCT02892734 |
NU 16B07
STU00203191
P30CA060553
NCI-2016-01038 |
|
September 5, 2017 |
April 2019 |
September 2020 |
September 8, 2016 |
September 11, 2017 |
|
- Northwestern University
Chicago, Illinois, United States
|
| 43 |
NCT00003042 |
Active, not recruiting |
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer |
|
- Biological: filgrastim
- Drug: cisplatin
- Drug: cyclophosphamide
- (and 8 more...)
|
Interventional |
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to progression at year 5
- Feasibility at year 5
- Overall survival at year 5
|
60 |
All |
up to 60 Years (Child, Adult) |
NCT00003042 |
96139
P30CA033572
CHNMC-96139
NCI-G97-1288
CDR0000065672 |
|
May 1997 |
September 2018 |
September 2018 |
January 27, 2003 |
September 27, 2017 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
|
| 44 |
NCT00254592 |
Active, not recruiting
Has Results |
Neoadjuvant Treatment of Breast Cancer |
|
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- Drug: Carboplatin
- (and 4 more...)
|
Interventional |
Phase 2 |
- University of California, Irvine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Clinical Response to the Dose Dense Regimen
|
43 |
Female |
18 Years and older (Adult, Senior) |
NCT00254592 |
UCI 05-38
2005-4550 |
|
October 2005 |
September 4, 2013 |
December 28, 2018 |
November 16, 2005 |
February 9, 2018 |
November 11, 2013 |
- Chao Family Comprehensive Cancer Center
Orange, California, United States
|
| 45 |
NCT02658812 |
Active, not recruiting |
Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence |
|
- Drug: Talimogene Laherparepvec (T-VEC)
- Other: Photographs
- Behavioral: Follow-Up Visit/Phone Call
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Amgen
- M.D. Anderson Cancer Center
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control Rate
- Progression Free Survival (PFS)
|
10 |
Female |
18 Years and older (Adult, Senior) |
NCT02658812 |
2014-0034
NCI-2016-00199 |
|
August 1, 2016 |
August 2021 |
August 2022 |
January 20, 2016 |
April 26, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 46 |
NCT01894451 |
Active, not recruiting |
Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy |
- Inflammatory Breast Carcinoma
|
- Drug: 89Zr-bevacizumab
- Procedure: FDG-PET/CT
- Procedure: MRI scan
- Procedure: Tumor biopsies
|
Interventional |
Early Phase 1 |
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
- Dana-Farber Cancer Institute
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Quality Control Standards for Radiopharmamceuticals and Number of Successfully Acquired 89Zr-bevacizumab-PET/CT scans
- Number of related adverse events after the intravenous administration of 89Zr-bevacizumab.
- Biodistribution of 89Zr-bevacizumab and individual organ and effective dose of 89Zr-bevacizumab
- (and 3 more...)
|
10 |
All |
21 Years and older (Adult, Senior) |
NCT01894451 |
13-147 |
|
June 2015 |
October 2019 |
October 2020 |
July 10, 2013 |
February 7, 2018 |
|
- Brigham and Womens Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
| 47 |
NCT00049114 |
Completed |
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer |
- Inflammatory Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- (and 2 more...)
|
- Drug: doxorubicin hydrochloride
- Drug: cyclophosphamide
- Drug: tipifarnib
- (and 3 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological complete response in the breast
- Proportion of patients who have a clinical complete response
- Grade 3 or 4 toxicities assessed using NCI CTCAE version 3.0
- (and 2 more...)
|
62 |
Female |
18 Years and older (Adult, Senior) |
NCT00049114 |
NCI-2012-02500
02-05-125
AECM-0205125
NCI-5598
CDR0000257811
N01CM62204 |
|
February 2003 |
January 2007 |
|
January 27, 2003 |
June 6, 2013 |
|
- Albert Einstein College of Medicine
Bronx, New York, United States
|
| 48 |
NCT01206881 |
Completed |
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer |
|
- Drug: pegylated liposomal doxorubicin
|
Interventional |
Phase 2 |
- Herlev Hospital
- Rigshospitalet, Denmark
- Odense University Hospital
- Aarhus University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- clinical response rate
- pathological response rate, response rate as defined by PET-CT scan, mammography and ultrasound, evaluation of toxicity of the combination regimen
|
45 |
Female |
18 Years to 75 Years (Adult, Senior) |
NCT01206881 |
PO5903, EudraCT 2008-007951-29 |
|
March 2009 |
May 2011 |
June 2011 |
September 22, 2010 |
July 4, 2011 |
|
- Aarhus University Hospital
Aarhus, Denmark - Rigshospitalet
Copenhagen, Denmark - Herlev Hospital
Herlev, Denmark - Odense University Hospital
Odense, Denmark
|
| 49 |
NCT01525966 |
Recruiting |
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer |
- Inflammatory Breast Cancer
- Stage IIA Breast Cancer
- Stage IIIA Breast Cancer
- (and 7 more...)
|
- Drug: carboplatin
- Drug: paclitaxel albumin-stabilized nanoparticle formulation
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- pCR or Symmans 0-1 pathological response
- Overall survival
- Progression-free survival
- Number of patients experiencing serious adverse events (SAEs) graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
69 |
Female |
19 Years and older (Adult, Senior) |
NCT01525966 |
11174
NCI-2012-00025 |
|
February 15, 2012 |
April 2018 |
April 2018 |
February 3, 2012 |
September 8, 2017 |
|
- City of Hope Medical Center
Duarte, California, United States - City of Hope- South Pasadena Cancer Center
South Pasadena, California, United States
|
| 50 |
NCT00004925 |
Completed |
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer |
|
- Biological: trastuzumab
- Drug: pegylated liposomal doxorubicin hydrochloride
|
Interventional |
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
- Memorial Sloan Kettering Cancer Center
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
Female |
18 Years and older (Adult, Senior) |
NCT00004925 |
99-054
CDR0000067609
LIPO-D9905
NCI-G00-1684 |
|
August 1999 |
August 2003 |
August 2003 |
May 14, 2003 |
June 19, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
Create an RSS feed from your search for:
Download the search results for: